Welcome to our dedicated page for BECTON DICKINSON & CO SEC filings (Ticker: BDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BECTON DICKINSON & CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BECTON DICKINSON & CO's regulatory disclosures and financial reporting.
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO and President of Life Sciences, reported a small stock sale. On 12/26/2025, he sold 74 shares of Becton Dickinson common stock at a price of $196.08 per share. After this transaction, he beneficially owned 16,506 shares directly.
The filing notes that this transaction was carried out under a Rule 10b5-1 trading plan that Feld adopted on February 7, 2025. Such plans allow insiders to pre-arrange trades according to set instructions, helping separate their personal trading activity from the timing of any nonpublic information they may hold.
Becton, Dickinson and Company is asking shareholders to vote at its virtual 2026 annual meeting on four items: electing 13 directors, ratifying Ernst & Young as independent auditor, approving named executive officer pay on an advisory basis, and increasing the shares available under its 2004 equity-based compensation plan by 3,935,000 shares.
The materials highlight record fiscal 2025 revenue of $21.8 billion, GAAP EPS of $5.82 and record adjusted diluted EPS of $14.40, supported by margin expansion from its BD Excellence program. BD returned $2.2 billion to shareholders through buybacks and dividends and marked its 54th consecutive annual dividend increase.
BD also describes the planned Reverse Morris Trust transaction combining its Biosciences and Diagnostic Solutions businesses with Waters Corporation, which is expected to generate about $4 billion in cash for BD and give its shareholders roughly 39% ownership of the new life sciences company, alongside extensive detail on governance, sustainability goals and risk oversight.
Becton Dickinson & Co executive Michael David Garrison reported selling 629 shares of common stock at $196.03 per share on December 17, 2025. After this sale, he directly owns 13,105 shares.
Garrison serves as EVP & Pres Med.Essntl&BioPharm, and the sale was made under a Rule 10b5-1 plan he adopted on August 13, 2025.
A shareholder of BDX has filed a notice under Rule 144 to sell 629 shares of common stock through Morgan Stanley Smith Barney LLC on the NYSE, with an approximate sale date of 12/17/2025. The planned sale has an aggregate market value of $123,529.31, compared with 285,418,551 shares of the same class reported as outstanding.
The shares to be sold were acquired on 11/26/2025 as Restricted Stock Units from the issuer, in an amount of 629 units, with the same date listed as the date of payment and the nature of payment noted as "N/A." By signing the notice, the seller represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.
Becton Dickinson & Co. reported the equity holdings of its interim CFO, Vitor Roque, as of 12/05/2025. He beneficially owns 4,477 shares of common stock, which includes shares held directly and restricted stock units granted under the company’s 2004 Employee and Director Equity-Based Compensation Plan.
Roque also holds multiple grants of stock appreciation rights covering various amounts of common stock, with grant dates from 11/26/2018 through 11/26/2025, exercise prices ranging from $222.60 to $251.06, and expiration dates between 11/26/2027 and 11/26/2034. These rights vest in four annual installments beginning one year from each grant date and are held directly. A power of attorney authorizing Donna Kalazdy to sign on Roque’s behalf is also referenced.
Becton Dickinson & Co. executive Michael Feld, who serves as EVP, CRO & President of Life Sciences, reported a small sale of company stock. On 12/01/2025, he sold 75 shares of Becton Dickinson common stock at a price of $193.36 per share. After this transaction, he beneficially owned 16,580 shares of Becton Dickinson common stock in direct ownership. The filing notes that this sale was made under a pre-arranged Rule 10b5-1 trading plan that Feld adopted on February 7, 2025, which is designed to allow insiders to sell shares according to a preset schedule.
Becton, Dickinson and Company reported an insider equity award for director Jacqueline Wright. On 12/01/2025, she acquired 180 shares of common stock through a grant of restricted stock units under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. The Form 4 shows the transaction as an acquisition at a stated price of $0, reflecting a stock-based compensation award rather than an open-market purchase. Following this grant, she beneficially owned 180 shares, held directly.
Becton, Dickinson and Company director reports stock award. A company director filed a Form 4 reporting the acquisition of 180 shares of Becton Dickinson common stock on 12/01/2025. The filing shows the transaction code "A," indicating an acquisition, at a price of $0 per share, and lists 180 shares beneficially owned directly after the transaction.
The footnote explains that these 180 shares represent restricted stock units granted under the Becton, Dickinson and Company 2004 Employee and Director Equity-Based Compensation Plan. This reflects routine equity-based compensation rather than an open-market purchase or sale.
Becton Dickinson & Co. reported a new director-level insider with no current stake in the company’s stock. A Form 3 was filed for a board member of Becton Dickinson, indicating that as of 12/01/2025 the reporting person beneficially owns 0 shares of the company’s securities and holds no listed derivative securities such as options or warrants.
The filing confirms the individual’s role as a Director and that the report is filed on an individual basis, not as part of a group. A power of attorney is on file, allowing an authorized person to sign Section 16 reports on the director’s behalf.